Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
January 08, 2024 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024 Halle (Saale) / Munich, Germany, January 8, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)...
Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
December 06, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress VIVIAD and VIVA-MIND studies both advancing as planned at 600mg twice daily following...
Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023
November 28, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023 Halle (Saale) / Munich, Germany, November 28, 2023 - Vivoryon Therapeutics N.V....
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference
November 07, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference Halle (Saale) / Munich, Germany, November 7, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)...
Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision
October 26, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision Both VIVIAD and VIVA-MIND...
Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated Dose
October 23, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed...
Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders
October 17, 2023 09:32 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders Multiple KOLs highlight varoglutamstat pathology, clinical development and clinical applicability of...
Vivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference Participation
October 05, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Announces Virtual R&D Event withKey Opinion Leaders and Upcoming Conference Participation Halle (Saale) / Munich, Germany, October 5, 2023 – Vivoryon Therapeutics N.V....
Vivoryon Therapeutics N.V. Extraordinary General Meeting Approved Appointment of New Executive Directors to the Board
September 15, 2023 07:57 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Extraordinary General MeetingApproved Appointment of New Executive Directors to the Board Halle (Saale) / Munich, Germany, September 15, 2023 – Vivoryon Therapeutics N.V....
Vivoryon Therapeutics N.V. Reports H1 2023 Financial Results and Highlights Operational Progress
September 07, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Reports H1 2023 Financial Results and Highlights Operational Progress Both VIVIAD and VIVA-MIND studies on track; final data from VIVIAD expected in Q1/2024, and a...